Close Menu
  • News
  • Medical
  • Technology
  • Nanomaterials
  • Research
  • Blog
    • Nasiol.com
  • Contact
    • Tech7685@gmail.com
What's Hot

Naturally derived nanoparticles show promise against cardiovascular and kidney disease

June 6, 2025

Ballistic electrons chart a new course for next-gen terahertz devices

June 6, 2025

‘Stealthy’ lipid nanoparticles give mRNA vaccines a makeover

June 5, 2025
Facebook X (Twitter) Instagram
Nanotech – Nanomaterials | Medical | Research | News Stories Updated Daily Nanotech – Nanomaterials | Medical | Research | News Stories Updated Daily
  • News
  • Medical
  • Technology
  • Nanomaterials
  • Research
  • Blog
    • Nasiol.com
  • Contact
    • Tech7685@gmail.com
Facebook X (Twitter) Instagram
Nanotech – Nanomaterials | Medical | Research | News Stories Updated Daily Nanotech – Nanomaterials | Medical | Research | News Stories Updated Daily
Home»Research»A Quantum Leap in Cancer Treatment: The Rise of Nanobiotix’s NBTXR3
Research

A Quantum Leap in Cancer Treatment: The Rise of Nanobiotix’s NBTXR3

October 17, 2023No Comments3 Mins Read
Facebook Twitter Pinterest Telegram LinkedIn Tumblr WhatsApp Email
A Quantum Leap in Cancer Treatment: The Rise of Nanobiotix’s NBTXR3
Share
Facebook Twitter LinkedIn Pinterest Telegram Email

Cancer remains one of the most formidable health challenges worldwide, affecting millions every year.

According to a study by Cancer Research UK, it’s estimated that there were 18.1 million new cancer diagnoses globally in 2020. This alarming figure underscores the rising trend in cancer diagnoses, the study states, “Worldwide there will be 28 million new cases of cancer each year by 2040.”

It’s not just about the overwhelming statistics but its profound impact on patients and their families. The treatment landscape, although progressing, still yearns for innovative breakthroughs.

NANOBIOTIX and NBTXR3

NANOBIOTIX, a biotechnology firm aiming to provide new treatment solutions for cancer patients, has recently welcomed Dr. Louis Kayitalire as their chief medical officer. Dr. Kayitalire boasts a prolific background in the biopharmaceutical sector, primarily focusing on oncology. He has been an integral part of the development and commercialization of various oncology therapeutics.

Laurent Levy, co-founder and chairman of NANOBIOTIX, praised Dr. Kayitalire’s innovative clinical acumen, asserting that his experience would be paramount in forwarding the company’s ventures, especially regarding NBTXR3.

Dr. Kayitalire previously held significant roles at major companies like F-star Biotechnology, Bristol-Myers Squibb, Celgene, and Eli Lilly. He expressed his excitement about the potential of NBTXR3 in changing the landscape of cancer treatment.

NBTXR3 Overview

NBTXR3, a unique oncology product, comprises hafnium oxide nanoparticles. Administered via a single intratumoral injection, it is then activated using radiotherapy. The primary goal is to cause significant tumor cell death in the injected area upon activation, which should then stimulate an adaptive immune response against the cancer.

See also  DNA Nanorobots Shaping Tomorrow's Innovations in Medicine and Ecology

NANOBIOTIX believes that due to its mode of action, NBTXR3 could be adapted for any solid tumor treatable with radiotherapy and combined with any therapeutic combination, especially immune checkpoint inhibitors.

Current evaluations for NBTXR3 involve its application in various solid tumors either as a standalone or in combination with anti-PD-1 immune checkpoint inhibitors.

Furthermore, NANOBIOTIX has embarked on collaborations to simultaneously develop the product while focusing on its primary developmental pathways. Partnerships include those with The University of Texas MD Anderson Cancer Center, LianBio, and recently with Janssen Pharmaceutica NV.

About NANOBIOTIX

Founded in 2003 and based in Paris, France, NANOBIOTIX is an advanced clinical biotechnology company. They are determined to redefine treatment outcomes for numerous patients by introducing groundbreaking physics-based therapeutic strategies.

The company holds over 20 umbrella patents linked to three distinct nanotechnology platforms. These platforms cater to oncology, bioavailability and biodistribution, and central nervous system disorders. Their principal focus is the development of NBTXR3, which has already received a CE marking in Europe for soft tissue sarcoma treatment under the brand name Hensify®.

While NANOBIOTIX remains a pivotal player in the field, other startups also contribute significantly to advancements in cancer treatment.

Among the many startups in this domain, Nanogenics stands out. They are a leading therapeutic provider that harnesses nanoscale technology and utilises siRNA to treat cancer and fibrotic diseases.

By leveraging their proprietary gene delivery technology, LipTide, they are adept at precisely delivering therapeutic siRNAs. Their premier drug, ECP-102, enhances the efficacy of chemotherapy by increasing the vulnerability of cancer cells to cell death.

See also  Gold nanodots can help boost cancer cell response to ultrasound treatment

Conclusion

The evolving landscape of cancer treatment is witnessing groundbreaking advancements spearheaded by entities like NANOBIOTIX. With the introduction of pioneering therapies, the future holds promise for more effective and diverse solutions in battling this global health crisis. Similarly, the contributions of startups such as Nanogenics emphasise a collective drive in the biotech community to push boundaries, offering hope and a brighter prognosis for patients worldwide.

COMPANIES TO WATCH:

Nanogenics, Nanobiotics

Source/Image

Author:

Kate Sivess-Symes

Content Producer and Writer

Nano Magazine | The Breakthrough

Source link

cancer Leap Nanobiotixs NBTXR3 quantum rise Treatment
Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

Related Posts

Drug-loaded nanoparticles can enhance precision and safety of ultrasound tumor treatment

May 27, 2025

Biosensor uses pH-responsive DNA nanoswitches for highly sensitive bladder cancer detection in urine

May 24, 2025

Depositing quantum dots on corrugated chips improves photodetector capabilities

May 8, 2025

Nanoparticle treatment combined with radiation therapy significantly improves glioblastoma survival in mice

May 3, 2025

Quantum confinement explains the dramatic rise of electrical resistivity in few-nanometers-thick silicon sheets

April 27, 2025

In What Ways Can Nanosensors Be Used to Detect Cancer?

April 22, 2025

Comments are closed.

Top Articles
News

Lipid Nanoparticles vs Liposomes: Key Differences Explained

News

Mini liver model innovations promise more effective drug testing

News

The first microrobots capable of navigating within groups of cells and stimulating individual cells

Editors Picks

Naturally derived nanoparticles show promise against cardiovascular and kidney disease

June 6, 2025

Ballistic electrons chart a new course for next-gen terahertz devices

June 6, 2025

‘Stealthy’ lipid nanoparticles give mRNA vaccines a makeover

June 5, 2025

Single-layer waveguide display uses achromatic metagratings for more compact augmented reality eyewear

June 5, 2025
About Us
About Us

Your go-to source for the latest nanotechnology breakthroughs. Explore innovations, applications, and implications shaping the future at the molecular level. Stay informed, embrace the nano-revolution.

We're accepting new partnerships right now.

Facebook X (Twitter) Instagram Pinterest
Our Picks

Nanocrystal Breakthrough Transforms Infrared Light Conversion

September 16, 2023

Polymeric nanomaterials can detect harmful substances in extreme environments

December 2, 2024

The ‘one-pot’ nanosheet method catalyzing a green energy revolution

December 21, 2023

Subscribe to Updates

Get the latest creative Nano Tech news from Elnano.com

© 2025 Elnano.com - All rights reserved.
  • Contact
  • Privacy Policy
  • Terms & Conditions

Type above and press Enter to search. Press Esc to cancel.

Cleantalk Pixel